AI assistant
Viking Therapeutics, Inc. — Director's Dealing 2021
Sep 30, 2021
31359_dirs_2021-09-30_1006f6e9-0005-492a-b497-d2e75bdb23e3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Viking Therapeutics, Inc. (VKTX)
CIK: 0001607678
Period of Report: 2021-09-28
Reporting Person: Mancini Marianna (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-28 | Common Stock, par value $0.00001 per share | A | 6667 | $0.00 | Acquired | 180374 | Direct |
| 2021-09-28 | Common Stock, par value $0.00001 per share | F | 2839 | $6.50 | Disposed | 177535 | Direct |
Footnotes
F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2020, 33.33% of which vested on September 28, 2021 upon the achievement of a non-financial performance goal.
F2: Includes 3,755 shares acquired on May 20, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award.